Ignite Creation Date:
2025-12-24 @ 7:39 PM
Ignite Modification Date:
2025-12-25 @ 5:19 PM
Study NCT ID:
NCT00337103
Status:
COMPLETED
Last Update Posted:
2020-06-18
First Post:
2006-06-13
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Serbia']}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C490954', 'term': 'eribulin'}, {'id': 'D000069287', 'term': 'Capecitabine'}], 'ancestors': [{'id': 'D003841', 'term': 'Deoxycytidine'}, {'id': 'D003562', 'term': 'Cytidine'}, {'id': 'D011741', 'term': 'Pyrimidine Nucleosides'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D005472', 'term': 'Fluorouracil'}, {'id': 'D014498', 'term': 'Uracil'}, {'id': 'D011744', 'term': 'Pyrimidinones'}, {'id': 'D003853', 'term': 'Deoxyribonucleosides'}, {'id': 'D009705', 'term': 'Nucleosides'}, {'id': 'D009706', 'term': 'Nucleic Acids, Nucleotides, and Nucleosides'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'esi_oncmedinfo@eisai.com', 'phone': '1-888-274-2378', 'title': 'Eisai Medical Information', 'organization': 'Eisai Inc.'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': 'First dose of study drug (Baseline) up to 30 days after last dose of study drug (up to approximately 6 years 3 months)', 'description': 'Data was analyzed using Safety Population defined as all participants who received at least one dose of study treatment.', 'eventGroups': [{'id': 'EG000', 'title': 'Eribulin Mesylate 1.4 mg/m^2', 'description': 'Eribulin mesylate 1.4 mg/m\\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days', 'otherNumAtRisk': 544, 'deathsNumAtRisk': 544, 'otherNumAffected': 509, 'seriousNumAtRisk': 544, 'deathsNumAffected': 442, 'seriousNumAffected': 95}, {'id': 'EG001', 'title': 'Capecitabine 2.5 g/m^2/Day', 'description': 'Capecitabine : Capecitabine 2.5 g/m\\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days', 'otherNumAtRisk': 546, 'deathsNumAtRisk': 546, 'otherNumAffected': 489, 'seriousNumAtRisk': 546, 'deathsNumAffected': 459, 'seriousNumAffected': 115}], 'otherEvents': [{'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 292}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 87}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Leukopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 171}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 57}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 102}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 96}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Thrombocytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 27}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 29}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 91}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 82}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 83}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 79}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 67}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 27}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Oedema Peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 35}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 36}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Mucosal Inflammation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 26}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 35}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 121}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 131}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 77}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 154}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 63}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 89}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 42}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 46}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Abdominal Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 32}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 46}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Abdominal Pain Upper', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 31}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 39}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Stomatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 27}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 31}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Alopecia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 188}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 22}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Peripheral Sensory Neuropathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 73}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 38}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 67}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 55}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 30}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 29}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Back Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 55}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 43}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Bone Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 50}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 42}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Pain in Extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 47}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 37}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 42}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 31}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 30}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 8}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Urinary Tract Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 29}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 26}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 49}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 51}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 45}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 44}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Decreased Appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 68}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 80}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Alanine Aminotransferase Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 47}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 23}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Aspartate Aminotransferase Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 43}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 27}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Tumour Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 29}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 22}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Hyperbilirubinaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 38}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Palmar-Plantar Erythrodysaesthesia Syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 244}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}], 'seriousEvents': [{'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 13}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 17}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Respiratory Failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 7}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Pleural Effusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Pulmonary Embolism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 3}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Hydrothorax', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Acute Respiratory Failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Epistaxis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Tracheal Stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Respiratory Distress', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Dyspnoea Exertional', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Pneumothorax', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Wheezing', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Febrile Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 4}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Leukopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Pancytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Thrombocytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 5}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 4}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 4}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Death', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'General Physical Health Deterioration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 3}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Multi-Organ Failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Extravasation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Influenza Like Illness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Sudden Death', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Mucosal Inflammation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Generalized Edema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Injection Site Extravasation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Oedema Peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 4}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Cerebrovascular Accident', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Spinal Cord Compression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Convulsion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Facial Paresis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Myoclonic Epilepsy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Partial Seizures', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Peripheral Motor Neuropathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Peripheral Sensory Neuropathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Transient Ischaemic Attack', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Depressed Level of Consciousness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Aphasia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Cerebellar Infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Coma Hepatic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Dysgeuesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Intracranial Pressure Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Lethargy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Simple Partial Seizures', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Somnolence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Bronchopneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Hepatitis C', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Lung Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Pneumonia Klebsiella', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Respiratory Tract Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Soft Tissue Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Upper Respiratory Tract Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Urinary Tract Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Cellulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Staphylococcal Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Subcutaneous Abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Neoplasm Malignant', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 4}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Metastases to Liver', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Metastases to Meninges', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Metastases to Ovary', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Metastases to Peritoneum', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Oncologic Complication', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 2}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Tumour Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 2}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Malignant Ascites', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Malignant Pleural Effusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Metastases to Central Nervous System', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Metastases to Pleura', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Rectal Cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 9}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Abdominal Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 15}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 7}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Gastrointestinal Haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Haematemesis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Haematochezia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Haemorrhoids', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Intestinal Ischaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Dysphagia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Cardiopulmonary Failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Myocardial Infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Pericardial Effusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Angina Pectoris', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Left Ventricular Dysfunction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Cardiac Failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 2}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Acute Myocardial Infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Bradycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Cardiac Tamponade', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Cardio-respiratory Arrest', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Cardiogenic Shock', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Femur Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 2}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Accidental Overdose', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Femoral Neck Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Hip Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Humerus Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Lumbar Vertebral Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Joint Dislocation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Dehydration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 9}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Hyperglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Decreased Appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Hypercalcaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Electrolyte Imbalance', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Hypokalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Hyponatraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Deep Vein Thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 3}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Hypotension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Thrombophlebitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Shock Haemorrhagic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Back Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Muscular Weakness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Pathological Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Bone Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Hepatitis Toxic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Hepatic Failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Cholelithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Renal Failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Renal Failure Acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Haematuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Hydronephrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Haemoglobin Decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Aspartate Aminotransferase Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Hepatic Enzyme Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Troponin Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Hypersensitivity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Immune system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Vertigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Palmar-Plantar Erythrodysaesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 2}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Vaginal Haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Malignant Breast Lump Removal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Intestinal Obstruction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Stomatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Confusional State', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Mental status changes', 'stats': [{'groupId': 'EG000', 'numAtRisk': 544, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 546, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Overall Survival (OS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '554', 'groupId': 'OG000'}, {'value': '548', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Eribulin Mesylate 1.4 mg/m^2', 'description': 'Eribulin mesylate 1.4 mg/m\\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.'}, {'id': 'OG001', 'title': 'Capecitabine 2.5 g/m^2/Day', 'description': 'Capecitabine : Capecitabine 2.5 g/m\\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '484', 'groupId': 'OG000', 'lowerLimit': '462', 'upperLimit': '536'}, {'value': '440', 'groupId': 'OG001', 'lowerLimit': '400', 'upperLimit': '487'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'From date of randomization until date of death from any cause, assessed up to data cutoff date of 12 Mar 2012, or up to approximately 6 years', 'description': 'OS was measured from the date of randomization until the date of death from any cause, or the last date the participant was known to be alive. Participants who were lost to follow-up or who were alive at the date of data cutoff were censored. The censoring rules for OS were as follows: 1) if the participant was still alive at data cutoff, the date of data cutoff was considered the end date, and 2) if the participant was lost to follow-up before data cutoff, the date they were last known to be alive was considered the end date. Participants who survived past the end of the study were counted as in the full study period. If death occurred after data cutoff, the end date was to be censored at the time of data cutoff.', 'unitOfMeasure': 'days', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Data was analyzed using the Intent-to-Treat (ITT) Population defined as all participants who were randomized.'}, {'type': 'PRIMARY', 'title': 'Progression Free Survival (PFS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '554', 'groupId': 'OG000'}, {'value': '548', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Eribulin Mesylate 1.4 mg/m^2', 'description': 'Eribulin mesylate 1.4 mg/m\\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.'}, {'id': 'OG001', 'title': 'Capecitabine 2.5 g/m^2/Day', 'description': 'Capecitabine : Capecitabine 2.5 g/m\\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '126', 'groupId': 'OG000', 'lowerLimit': '106', 'upperLimit': '131'}, {'value': '129', 'groupId': 'OG001', 'lowerLimit': '120', 'upperLimit': '147'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'From date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date of 12 Mar 2012 or up to approximately 6 years', 'description': 'PFS was defined as the time (in days) from the date of randomization to the date of the first sign of disease progression based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 (v 1.1) or date of death, regardless of cause. Disease progression was measured by computed tomography (CT) and magnetic resonance imaging (MRI) performed on lesions targeted at baseline for tumor assessment. Disease progression (as assessed by independent review of the imaging scans) per RECIST v 1.1 was defined as at least a 20% increase in the sum of the diameters of the target lesions (taking as reference the smallest sum on study, including the baseline sum if that is the smallest), and an absolute increase of at least 5 millimeter (mm). Note that the appearance of one or more new lesions was also considered as disease progression.', 'unitOfMeasure': 'Days', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Data was analyzed using the ITT Population defined as all participants who were randomized.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Global Health Status/Quality of Life (QoL) Measured by European Organization for the Treatment of Cancer Quality of Life Core Questionnaire Scores Based on Core 30 Items (EORTC-QLQ-C30) at Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '438', 'groupId': 'OG000'}, {'value': '406', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Eribulin Mesylate 1.4 mg/m^2', 'description': 'Eribulin mesylate 1.4 mg/m\\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.'}, {'id': 'OG001', 'title': 'Capecitabine 2.5 g/m^2/Day', 'description': 'Capecitabine : Capecitabine 2.5 g/m\\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.1', 'spread': '19.23', 'groupId': 'OG000'}, {'value': '1.7', 'spread': '20.69', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 6', 'description': 'EORTC-QLQ-C30:cancer-specific instrument with 30 questions to assess the participant QoL. First 28 questions used to evaluate 5 functional scales (physical, role, cognitive, emotional, social), 3 symptom scales (fatigue, nausea and vomiting, pain) and other single items(dyspnoea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Each of these 28 questions assessed on 4-point scale(1=not at all, 2=a little, 3=quite a bit, 4=very much); functional scales: higher score=better level of functioning; symptom scale: higher score=more severe symptoms; for single items: higher score= more severe problem. Last 2 questions used to evaluate global health status (GHS)/QoL. Each question was assessed on 7-point scale (1=very poor to 7=excellent). Scores averaged, transformed to 0-100 scale; higher score=better quality of life/better level of functioning.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Data was analyzed using the ITT Population defined as all participants who were randomized. Here,"overall number of participants analyzed" are the participants who were evaluable for this outcome measure.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in European Organization for the Treatment of Cancer Quality of Life Core Questionnaire Scores Based on Breast Cancer Specific 23 Items (EORTC-QLQ- BR 23) at Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '554', 'groupId': 'OG000'}, {'value': '548', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Eribulin Mesylate 1.4 mg/m^2', 'description': 'Eribulin mesylate 1.4 mg/m\\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.'}, {'id': 'OG001', 'title': 'Capecitabine 2.5 g/m^2/Day', 'description': 'Capecitabine : Capecitabine 2.5 g/m\\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days.'}], 'classes': [{'title': 'Body Image', 'denoms': [{'units': 'Participants', 'counts': [{'value': '441', 'groupId': 'OG000'}, {'value': '411', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.7', 'spread': '21.26', 'groupId': 'OG000'}, {'value': '4.8', 'spread': '21.80', 'groupId': 'OG001'}]}]}, {'title': 'Sexual functioning', 'denoms': [{'units': 'Participants', 'counts': [{'value': '418', 'groupId': 'OG000'}, {'value': '381', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.2', 'spread': '14.75', 'groupId': 'OG000'}, {'value': '-0.1', 'spread': '16.62', 'groupId': 'OG001'}]}]}, {'title': 'Sexual enjoyment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '82', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.8', 'spread': '21.58', 'groupId': 'OG000'}, {'value': '3.1', 'spread': '17.49', 'groupId': 'OG001'}]}]}, {'title': 'Future perspective', 'denoms': [{'units': 'Participants', 'counts': [{'value': '439', 'groupId': 'OG000'}, {'value': '410', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '7.7', 'spread': '28.48', 'groupId': 'OG000'}, {'value': '10.0', 'spread': '30.84', 'groupId': 'OG001'}]}]}, {'title': 'Systemic therapy side effects', 'denoms': [{'units': 'Participants', 'counts': [{'value': '440', 'groupId': 'OG000'}, {'value': '415', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.5', 'spread': '15.55', 'groupId': 'OG000'}, {'value': '-1.2', 'spread': '14.73', 'groupId': 'OG001'}]}]}, {'title': 'Breast Symptoms', 'denoms': [{'units': 'Participants', 'counts': [{'value': '434', 'groupId': 'OG000'}, {'value': '407', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-3.4', 'spread': '16.55', 'groupId': 'OG000'}, {'value': '-3.6', 'spread': '16.20', 'groupId': 'OG001'}]}]}, {'title': 'Arm Symptoms', 'denoms': [{'units': 'Participants', 'counts': [{'value': '437', 'groupId': 'OG000'}, {'value': '411', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-4.2', 'spread': '17.94', 'groupId': 'OG000'}, {'value': '-3.4', 'spread': '18.65', 'groupId': 'OG001'}]}]}, {'title': 'Upset by hair loss', 'denoms': [{'units': 'Participants', 'counts': [{'value': '91', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-4.4', 'spread': '32.66', 'groupId': 'OG000'}, {'value': '-10.1', 'spread': '29.76', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 6', 'description': 'EORTC-QLQ-BR23:disease-specific module for breast cancer developed as a supplement for the EORTC-QLQ-C30 to assess quality of life of participants with breast cancer. The scores from 23 items of QLQ-BR23 included functional scales (body image, sexual functioning, sexual enjoyment, future perspective), symptom scales (systemic therapy side effects, breast symptoms, arm symptoms, upset by hair loss). Each item was rated on a scale of 1 to 4 to record level of intensity (1= not at all, 2= a little, 3= quite a bit, 4= very much) within each scales. Scores averaged and transformed to 0-100 scale. High score indicated high/better level of functioning/healthy functioning. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Data was analyzed using the ITT Population defined as all participants who were randomized. Here,"number analyzed" signifies the participants who were evaluable for this outcome measure for individual row.'}, {'type': 'SECONDARY', 'title': 'Objective Response Rate (ORR): Independent Review', 'denoms': [{'units': 'Participants', 'counts': [{'value': '554', 'groupId': 'OG000'}, {'value': '548', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Eribulin Mesylate 1.4 mg/m^2', 'description': 'Eribulin mesylate 1.4 mg/m\\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.'}, {'id': 'OG001', 'title': 'Capecitabine 2.5 g/m^2/Day', 'description': 'Capecitabine : Capecitabine 2.5 g/m\\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '11.0', 'groupId': 'OG000', 'lowerLimit': '8.5', 'upperLimit': '13.9'}, {'value': '11.5', 'groupId': 'OG001', 'lowerLimit': '8.9', 'upperLimit': '14.5'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From date of randomization until date of first documentation of CR or PR, assessed up to data cutoff date of 12 Mar 2012 or up to approximately 6 years', 'description': 'ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v 1.1). CR is defined as disappearance of all target legions and non-target lesions. All pathological lymph nodes (whether target and non-target), must have reduction in their short axis to less than 10 mm. PR is defined as at least 30% decrease in the sum of the long diameter LD (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Data was analyzed using the ITT Population defined as all participants who were randomized.'}, {'type': 'SECONDARY', 'title': 'Duration of Response (DOR): Independent Review', 'denoms': [{'units': 'Participants', 'counts': [{'value': '61', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Eribulin Mesylate 1.4 mg/m^2', 'description': 'Eribulin mesylate 1.4 mg/m\\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.'}, {'id': 'OG001', 'title': 'Capecitabine 2.5 g/m^2/Day', 'description': 'Capecitabine : Capecitabine 2.5 g/m\\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '198', 'groupId': 'OG000', 'lowerLimit': '150', 'upperLimit': '273'}, {'value': '330', 'groupId': 'OG001', 'lowerLimit': '208', 'upperLimit': '541'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'From first documented CR or PR until date of recurrent or progressive disease or death, assessed up to data cutoff of date of 12 Mar 2012 or up to approximately 6 years', 'description': 'DOR was defined as the time from first documented CR or PR until disease progression or death from any cause for those participants with a confirmed PR or CR measured by RECIST v1.1. CR defined as disappearance of all target and non-target lesions. All pathological lymph nodes(whether target and non-target), must have reduction in their short axis to less than 10 mm. PR defined as at least 30% decrease in the sum of the long diameter LD (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.', 'unitOfMeasure': 'days', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Data was analyzed using for a subset of participants in the ITT Population who had a response. Here, "overall number of participants analyzed" are the participants who were evaluable for this outcome measure.'}, {'type': 'SECONDARY', 'title': 'Overall Survival Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '554', 'groupId': 'OG000'}, {'value': '548', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Eribulin Mesylate 1.4 mg/m^2', 'description': 'Eribulin mesylate 1.4 mg/m\\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.'}, {'id': 'OG001', 'title': 'Capecitabine 2.5 g/m^2/Day', 'description': 'Capecitabine : Capecitabine 2.5 g/m\\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days.'}], 'classes': [{'title': 'At 1-year', 'categories': [{'measurements': [{'value': '0.644', 'groupId': 'OG000', 'lowerLimit': '0.604', 'upperLimit': '0.684'}, {'value': '0.580', 'groupId': 'OG001', 'lowerLimit': '0.538', 'upperLimit': '0.622'}]}]}, {'title': 'At 2-years', 'categories': [{'measurements': [{'value': '0.328', 'groupId': 'OG000', 'lowerLimit': '0.289', 'upperLimit': '0.368'}, {'value': '0.298', 'groupId': 'OG001', 'lowerLimit': '0.259', 'upperLimit': '0.337'}]}]}, {'title': 'At 3-years', 'categories': [{'measurements': [{'value': '0.178', 'groupId': 'OG000', 'lowerLimit': '0.144', 'upperLimit': '0.212'}, {'value': '0.145', 'groupId': 'OG001', 'lowerLimit': '0.113', 'upperLimit': '0.177'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From the date of randomization to Year 1, 2 and 3', 'description': "One-, two-, and three- year's survival rates were defined as the percentage of participants who were alive at one, two, and three years respectively, and estimated using the Kaplan-Meier method and Greenwood Formula.", 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Data was analyzed using the ITT Population defined as all participants who were randomized.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Pain Intensity by Visual Analog Scale (VAS) Until 30 Days After the Last Dose of Study Drug', 'denoms': [{'units': 'Participants', 'counts': [{'value': '431', 'groupId': 'OG000'}, {'value': '431', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Eribulin Mesylate 1.4 mg/m^2', 'description': 'Eribulin mesylate 1.4 mg/m\\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.'}, {'id': 'OG001', 'title': 'Capecitabine 2.5 g/m^2/Day', 'description': 'Capecitabine : Capecitabine 2.5 g/m\\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '-3.7', 'spread': '22.80', 'groupId': 'OG000'}, {'value': '0.4', 'spread': '22.90', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'First dose of study drug (Baseline) up to 30 days after last dose of study drug (up to approximately 6 years 3 months)', 'description': 'Pain intensity was measured by marking a single vertical line that crosses a 1-100 mm unmarked VAS scale. The left-end of the visual analog scale was labelled "least possible pain" and the right-end of the visual analog scale was labelled "worst possible pain". The pain rating ranged from 0 to 100, with a higher score indicating more pain. A negative change score indicated improvement.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Data was analyzed using the ITT Population defined as all participants who were randomized. Here, "overall number of participants analyzed" are the participants who were evaluable for the outcome measure.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Consumption of Analgesics During the Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '544', 'groupId': 'OG000'}, {'value': '546', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Eribulin Mesylate 1.4 mg/m^2', 'description': 'Eribulin mesylate 1.4 mg/m\\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.'}, {'id': 'OG001', 'title': 'Capecitabine 2.5 g/m^2/Day', 'description': 'Capecitabine : Capecitabine 2.5 g/m\\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '222', 'groupId': 'OG000'}, {'value': '196', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'First dose of study drug (Baseline) up to 30 days after last dose of study drug (up to approximately 6 years 3 months)', 'description': 'Participants took analgesics as concomitant pain medications which are defined as pain medications that (1) started before the first dose of study drug and were continuing at the time of the first dose of study drug, or (2) started on/after the day of the first dose of study drug up to 30 days after the last dose of study drug medication', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Data was analyzed using safety population defined as all participants who received at least one dose of study treatment.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '544', 'groupId': 'OG000'}, {'value': '546', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Eribulin Mesylate 1.4 mg/m^2', 'description': 'Eribulin mesylate 1.4 mg/m\\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.'}, {'id': 'OG001', 'title': 'Capecitabine 2.5 g/m^2/Day', 'description': 'Capecitabine : Capecitabine 2.5 g/m\\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days'}], 'classes': [{'title': 'TEAEs', 'categories': [{'measurements': [{'value': '512', 'groupId': 'OG000'}, {'value': '494', 'groupId': 'OG001'}]}]}, {'title': 'SAEs', 'categories': [{'measurements': [{'value': '95', 'groupId': 'OG000'}, {'value': '115', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'First dose of study drug (Baseline) up to 30 days after last dose of study drug (up to approximately 6 years 3 months)', 'description': 'TEAEs included both SAEs as well as non-SAEs.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Data was analyzed using safety population defined as all participants who received at least one dose of study treatment.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Treatment-emergent Markedly Abnormal Laboratory Parameter Values', 'denoms': [{'units': 'Participants', 'counts': [{'value': '544', 'groupId': 'OG000'}, {'value': '546', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Eribulin Mesylate 1.4 mg/m^2', 'description': 'Eribulin mesylate 1.4 mg/m\\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.'}, {'id': 'OG001', 'title': 'Capecitabine 2.5 g/m^2/Day', 'description': 'Capecitabine : Capecitabine 2.5 g/m\\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '362', 'groupId': 'OG000'}, {'value': '224', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'First dose of study drug (Baseline) up to 30 days after last dose of study drug (up to approximately 6 years 3 months)', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Data was analyzed using safety population defined as all participants who received at least one dose of study treatment.'}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Took at Least One Concomitant Medication', 'denoms': [{'units': 'Participants', 'counts': [{'value': '544', 'groupId': 'OG000'}, {'value': '546', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Eribulin Mesylate 1.4 mg/m^2', 'description': 'Eribulin mesylate 1.4 mg/m\\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.'}, {'id': 'OG001', 'title': 'Capecitabine 2.5 g/m^2/Day', 'description': 'Capecitabine : Capecitabine 2.5 g/m\\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '496', 'groupId': 'OG000'}, {'value': '483', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'First dose of study drug (Baseline) up to 30 days after last dose of study drug (up to approximately 6 years 3 months)', 'description': 'Concomitant medications included medications that either (1) started before the first dose of study drug and were continuing at the time of the first dose of study drug, or (2) started on or after the first dose of study drug up to 30 days after the last dose of study drug.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Data was analyzed using safety population defined as all participants who received at least one dose of study treatment.'}, {'type': 'SECONDARY', 'title': 'Duration of Eribulin Mesylate Exposure', 'denoms': [{'units': 'Participants', 'counts': [{'value': '544', 'groupId': 'OG000'}, {'value': '546', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Eribulin Mesylate 1.4 mg/m^2', 'description': 'Eribulin mesylate 1.4 mg/m\\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.'}, {'id': 'OG001', 'title': 'Capecitabine 2.5 g/m^2/Day', 'description': 'Capecitabine : Capecitabine 2.5 g/m\\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days.'}], 'classes': [{'title': 'At primary analysis completion stage', 'denoms': [{'units': 'Participants', 'counts': [{'value': '544', 'groupId': 'OG000'}, {'value': '546', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '125.0', 'groupId': 'OG000', 'lowerLimit': '21', 'upperLimit': '1372'}, {'value': '119.0', 'groupId': 'OG001', 'lowerLimit': '21', 'upperLimit': '1442'}]}]}, {'title': 'At final analysis completion stage', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1743.0', 'groupId': 'OG000', 'lowerLimit': '1561', 'upperLimit': '2219'}, {'value': '1506.0', 'groupId': 'OG001', 'lowerLimit': '1175', 'upperLimit': '2296'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Up to approximately 6 years for primary analysis completion stage, Up to approximately 6 years 2 months for final analysis completion stage', 'description': 'Data have been reported per primary analysis completion stage and final analysis completion stage. After primary analysis completion (at cutoff date of 12 March 2012), only 10 participants were still receiving study treatment.', 'unitOfMeasure': 'days', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Data was analyzed using safety population defined as all participants who received at least one dose of study treatment. Here, "number analyzed" signifies the participants who were evaluable at individual stage for this outcome measure.'}, {'type': 'SECONDARY', 'title': 'Plasma Concentrations of Eribulin Mesylate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '173', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Eribulin Mesylate 1.4 mg/m^2', 'description': 'Eribulin mesylate 1.4 mg/m\\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.'}], 'classes': [{'title': '5-10 minutes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '172', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '415.8', 'spread': '719.5', 'groupId': 'OG000'}]}]}, {'title': '15-30 minutes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '57', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '152.6', 'spread': '70.51', 'groupId': 'OG000'}]}]}, {'title': '30-60 minutes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '58', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '95.5', 'spread': '87.90', 'groupId': 'OG000'}]}]}, {'title': '60-90 minutes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '58', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '52.7', 'spread': '79.33', 'groupId': 'OG000'}]}]}, {'title': '2-4 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '85', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '20.7', 'spread': '32.81', 'groupId': 'OG000'}]}]}, {'title': '4-8 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '78', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '10.0', 'spread': '5.40', 'groupId': 'OG000'}]}]}, {'title': '10-24 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.8', 'spread': '3.72', 'groupId': 'OG000'}]}]}, {'title': '48-72 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.7', 'spread': '2.58', 'groupId': 'OG000'}]}]}, {'title': '72-96 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.4', 'spread': '1.60', 'groupId': 'OG000'}]}]}, {'title': '96-120 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '7.6', 'spread': '38.75', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Cycle 1 Day 1: 5-10 minutes(min), 15-30 min, 30-60 min, 60-90 min, 2-4 hours(hrs), 4-8 hrs, 10-24 hrs, 48-72 hrs, 72-96 hrs, 96-120 hrs after the start of infusion of Eribulin mesylate (Duration of each cycle is 21 days)', 'unitOfMeasure': 'nanogram per milliliter (ng/mL)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Pharmacokinetic (PK) analysis set included all participants who have received at least one dose of E7389 and have at least one quantifiable E7389 concentration. Here, "number analyzed" signifies the participants who were evaluable for this outcome measure for given time points.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Eribulin Mesylate 1.4 mg/m^2', 'description': 'Eribulin mesylate 1.4 milligram per meter square (mg/m\\^2) intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.'}, {'id': 'FG001', 'title': 'Capecitabine 2.5 g/m^2/Day', 'description': 'Capecitabine : Capecitabine 2.5 gram per meter square per day (g/m\\^2/day) administered orally twice daily in two equal doses on Days 1 to 14 every 21 days.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '554'}, {'groupId': 'FG001', 'numSubjects': '548'}]}, {'type': 'Treated (Safety Population)', 'achievements': [{'groupId': 'FG000', 'numSubjects': '544'}, {'groupId': 'FG001', 'numSubjects': '546'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '554'}, {'groupId': 'FG001', 'numSubjects': '548'}]}], 'dropWithdraws': [{'type': 'Progressive Disease', 'reasons': [{'groupId': 'FG000', 'numSubjects': '414'}, {'groupId': 'FG001', 'numSubjects': '410'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '45'}, {'groupId': 'FG001', 'numSubjects': '59'}]}, {'type': 'Subject Choice', 'reasons': [{'groupId': 'FG000', 'numSubjects': '34'}, {'groupId': 'FG001', 'numSubjects': '27'}]}, {'type': 'Clinical Progression', 'reasons': [{'groupId': 'FG000', 'numSubjects': '27'}, {'groupId': 'FG001', 'numSubjects': '24'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '15'}, {'groupId': 'FG001', 'numSubjects': '14'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '5'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '6'}]}, {'type': 'Entry Criteria Not Met', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}], 'preAssignmentDetails': 'A total of 1276 participants were enrolled and screened, of which 174 were screen failures and 1102 were randomized in the study. Of the randomized participants, 1090 participants received the study treatment.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '554', 'groupId': 'BG000'}, {'value': '548', 'groupId': 'BG001'}, {'value': '1102', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Eribulin Mesylate 1.4 mg/m^2', 'description': 'Eribulin mesylate 1.4 mg/m\\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.'}, {'id': 'BG001', 'title': 'Capecitabine 2.5 g/m^2/Day', 'description': 'Capecitabine : Capecitabine 2.5 g/m\\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '53.8', 'spread': '10.37', 'groupId': 'BG000'}, {'value': '52.8', 'spread': '10.20', 'groupId': 'BG001'}, {'value': '53.3', 'spread': '10.29', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '554', 'groupId': 'BG000'}, {'value': '548', 'groupId': 'BG001'}, {'value': '1102', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '18', 'groupId': 'BG000'}, {'value': '18', 'groupId': 'BG001'}, {'value': '36', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '15', 'groupId': 'BG000'}, {'value': '16', 'groupId': 'BG001'}, {'value': '31', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '496', 'groupId': 'BG000'}, {'value': '495', 'groupId': 'BG001'}, {'value': '991', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '25', 'groupId': 'BG000'}, {'value': '19', 'groupId': 'BG001'}, {'value': '44', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 1276}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2006-09-20', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-01', 'completionDateStruct': {'date': '2017-12-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-05-28', 'studyFirstSubmitDate': '2006-06-13', 'resultsFirstSubmitDate': '2013-07-31', 'studyFirstSubmitQcDate': '2006-06-13', 'lastUpdatePostDateStruct': {'date': '2020-06-18', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2013-07-31', 'studyFirstPostDateStruct': {'date': '2006-06-15', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2013-09-30', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2012-03-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Overall Survival (OS)', 'timeFrame': 'From date of randomization until date of death from any cause, assessed up to data cutoff date of 12 Mar 2012, or up to approximately 6 years', 'description': 'OS was measured from the date of randomization until the date of death from any cause, or the last date the participant was known to be alive. Participants who were lost to follow-up or who were alive at the date of data cutoff were censored. The censoring rules for OS were as follows: 1) if the participant was still alive at data cutoff, the date of data cutoff was considered the end date, and 2) if the participant was lost to follow-up before data cutoff, the date they were last known to be alive was considered the end date. Participants who survived past the end of the study were counted as in the full study period. If death occurred after data cutoff, the end date was to be censored at the time of data cutoff.'}, {'measure': 'Progression Free Survival (PFS)', 'timeFrame': 'From date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date of 12 Mar 2012 or up to approximately 6 years', 'description': 'PFS was defined as the time (in days) from the date of randomization to the date of the first sign of disease progression based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 (v 1.1) or date of death, regardless of cause. Disease progression was measured by computed tomography (CT) and magnetic resonance imaging (MRI) performed on lesions targeted at baseline for tumor assessment. Disease progression (as assessed by independent review of the imaging scans) per RECIST v 1.1 was defined as at least a 20% increase in the sum of the diameters of the target lesions (taking as reference the smallest sum on study, including the baseline sum if that is the smallest), and an absolute increase of at least 5 millimeter (mm). Note that the appearance of one or more new lesions was also considered as disease progression.'}], 'secondaryOutcomes': [{'measure': 'Change From Baseline in Global Health Status/Quality of Life (QoL) Measured by European Organization for the Treatment of Cancer Quality of Life Core Questionnaire Scores Based on Core 30 Items (EORTC-QLQ-C30) at Week 6', 'timeFrame': 'Baseline and Week 6', 'description': 'EORTC-QLQ-C30:cancer-specific instrument with 30 questions to assess the participant QoL. First 28 questions used to evaluate 5 functional scales (physical, role, cognitive, emotional, social), 3 symptom scales (fatigue, nausea and vomiting, pain) and other single items(dyspnoea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Each of these 28 questions assessed on 4-point scale(1=not at all, 2=a little, 3=quite a bit, 4=very much); functional scales: higher score=better level of functioning; symptom scale: higher score=more severe symptoms; for single items: higher score= more severe problem. Last 2 questions used to evaluate global health status (GHS)/QoL. Each question was assessed on 7-point scale (1=very poor to 7=excellent). Scores averaged, transformed to 0-100 scale; higher score=better quality of life/better level of functioning.'}, {'measure': 'Change From Baseline in European Organization for the Treatment of Cancer Quality of Life Core Questionnaire Scores Based on Breast Cancer Specific 23 Items (EORTC-QLQ- BR 23) at Week 6', 'timeFrame': 'Baseline and Week 6', 'description': 'EORTC-QLQ-BR23:disease-specific module for breast cancer developed as a supplement for the EORTC-QLQ-C30 to assess quality of life of participants with breast cancer. The scores from 23 items of QLQ-BR23 included functional scales (body image, sexual functioning, sexual enjoyment, future perspective), symptom scales (systemic therapy side effects, breast symptoms, arm symptoms, upset by hair loss). Each item was rated on a scale of 1 to 4 to record level of intensity (1= not at all, 2= a little, 3= quite a bit, 4= very much) within each scales. Scores averaged and transformed to 0-100 scale. High score indicated high/better level of functioning/healthy functioning. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL.'}, {'measure': 'Objective Response Rate (ORR): Independent Review', 'timeFrame': 'From date of randomization until date of first documentation of CR or PR, assessed up to data cutoff date of 12 Mar 2012 or up to approximately 6 years', 'description': 'ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v 1.1). CR is defined as disappearance of all target legions and non-target lesions. All pathological lymph nodes (whether target and non-target), must have reduction in their short axis to less than 10 mm. PR is defined as at least 30% decrease in the sum of the long diameter LD (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.'}, {'measure': 'Duration of Response (DOR): Independent Review', 'timeFrame': 'From first documented CR or PR until date of recurrent or progressive disease or death, assessed up to data cutoff of date of 12 Mar 2012 or up to approximately 6 years', 'description': 'DOR was defined as the time from first documented CR or PR until disease progression or death from any cause for those participants with a confirmed PR or CR measured by RECIST v1.1. CR defined as disappearance of all target and non-target lesions. All pathological lymph nodes(whether target and non-target), must have reduction in their short axis to less than 10 mm. PR defined as at least 30% decrease in the sum of the long diameter LD (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.'}, {'measure': 'Overall Survival Rate', 'timeFrame': 'From the date of randomization to Year 1, 2 and 3', 'description': "One-, two-, and three- year's survival rates were defined as the percentage of participants who were alive at one, two, and three years respectively, and estimated using the Kaplan-Meier method and Greenwood Formula."}, {'measure': 'Change From Baseline in Pain Intensity by Visual Analog Scale (VAS) Until 30 Days After the Last Dose of Study Drug', 'timeFrame': 'First dose of study drug (Baseline) up to 30 days after last dose of study drug (up to approximately 6 years 3 months)', 'description': 'Pain intensity was measured by marking a single vertical line that crosses a 1-100 mm unmarked VAS scale. The left-end of the visual analog scale was labelled "least possible pain" and the right-end of the visual analog scale was labelled "worst possible pain". The pain rating ranged from 0 to 100, with a higher score indicating more pain. A negative change score indicated improvement.'}, {'measure': 'Number of Participants With Consumption of Analgesics During the Study', 'timeFrame': 'First dose of study drug (Baseline) up to 30 days after last dose of study drug (up to approximately 6 years 3 months)', 'description': 'Participants took analgesics as concomitant pain medications which are defined as pain medications that (1) started before the first dose of study drug and were continuing at the time of the first dose of study drug, or (2) started on/after the day of the first dose of study drug up to 30 days after the last dose of study drug medication'}, {'measure': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)', 'timeFrame': 'First dose of study drug (Baseline) up to 30 days after last dose of study drug (up to approximately 6 years 3 months)', 'description': 'TEAEs included both SAEs as well as non-SAEs.'}, {'measure': 'Number of Participants With Treatment-emergent Markedly Abnormal Laboratory Parameter Values', 'timeFrame': 'First dose of study drug (Baseline) up to 30 days after last dose of study drug (up to approximately 6 years 3 months)'}, {'measure': 'Number of Participants Who Took at Least One Concomitant Medication', 'timeFrame': 'First dose of study drug (Baseline) up to 30 days after last dose of study drug (up to approximately 6 years 3 months)', 'description': 'Concomitant medications included medications that either (1) started before the first dose of study drug and were continuing at the time of the first dose of study drug, or (2) started on or after the first dose of study drug up to 30 days after the last dose of study drug.'}, {'measure': 'Duration of Eribulin Mesylate Exposure', 'timeFrame': 'Up to approximately 6 years for primary analysis completion stage, Up to approximately 6 years 2 months for final analysis completion stage', 'description': 'Data have been reported per primary analysis completion stage and final analysis completion stage. After primary analysis completion (at cutoff date of 12 March 2012), only 10 participants were still receiving study treatment.'}, {'measure': 'Plasma Concentrations of Eribulin Mesylate', 'timeFrame': 'Cycle 1 Day 1: 5-10 minutes(min), 15-30 min, 30-60 min, 60-90 min, 2-4 hours(hrs), 4-8 hrs, 10-24 hrs, 48-72 hrs, 72-96 hrs, 96-120 hrs after the start of infusion of Eribulin mesylate (Duration of each cycle is 21 days)'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True}, 'conditionsModule': {'conditions': ['Metastatic Breast Cancer']}, 'referencesModule': {'references': [{'pmid': '27398025', 'type': 'DERIVED', 'citation': 'Twelves C, Awada A, Cortes J, Yelle L, Velikova G, Olivo MS, Song J, Dutcus CE, Kaufman PA. Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer. Breast Cancer (Auckl). 2016 Jun 28;10:77-84. doi: 10.4137/BCBCR.S39615. eCollection 2016.'}, {'pmid': '27391598', 'type': 'DERIVED', 'citation': 'Twelves C, Cortes J, Kaufman PA, Yelle L, Awada A, Binder TA, Olivo M, Song J, O\'Shaughnessy JA, Jove M, Perez EA. "New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Res. 2015 Dec 9;17(1):150. doi: 10.1186/s13058-015-0657-1.'}, {'pmid': '26567010', 'type': 'DERIVED', 'citation': 'Cortes J, Hudgens S, Twelves C, Perez EA, Awada A, Yelle L, McCutcheon S, Kaufman PA, Forsythe A, Velikova G. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Res Treat. 2015 Dec;154(3):509-20. doi: 10.1007/s10549-015-3633-7. Epub 2015 Nov 14.'}, {'pmid': '25605862', 'type': 'DERIVED', 'citation': 'Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015 Feb 20;33(6):594-601. doi: 10.1200/JCO.2013.52.4892. Epub 2015 Jan 20.'}, {'pmid': '20299316', 'type': 'DERIVED', 'citation': 'Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2010 Apr;10(2):160-3. doi: 10.3816/CBC.2010.n.023.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to compare E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer who are refractory to the most recent chemotherapy. This is an open-label, randomized, two-parallel arm study. Patients will be randomized to receive either E7389 or capecitabine on a one-to-one ratio.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Female patients with histologically or cytologically confirmed carcinoma of the breast. Every effort should be made to ensure that paraffin embedded tissue or slides from the diagnostic biopsy or surgical specimen are available for confirmation of diagnosis.\n2. Patients with locally advanced or metastatic disease who have received up to three prior chemotherapy regimens, and no more than two prior regimens for advanced and/or metastatic disease.\n\n * Regimens must have included an anthracycline (e.g., doxorubicin, epirubicin) and a taxane (e.g., paclitaxel, docetaxel), either in combination or in separate regimens.\n * Patients with known human epidermal growth factor 2 (HER2/neu) over-expressing tumors may additionally have been treated with trastuzumab in centers where this treatment is available.\n * Patients with known estrogen and/or progesterone receptor-expressing tumors may have additionally been treated with hormonal therapy.\n3. Resolution of all chemotherapy or radiation-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy \\<= Grade 2 and alopecia.\n4. Age \\>= 18 years.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.\n6. Life expectancy of \\>= 3 months.\n7. Adequate renal function as evidenced by serum creatinine \\<1.5 mg/dL or calculated creatinine clearance \\> 50 mL/minute (min) per the Cockcroft and Gault formula.\n8. Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) \\>= 1.5 x 10\\^9/L, hemoglobin \\>= 10.0 g/dL (a hemoglobin \\< 10.0 g/dL acceptable if it is corrected by growth factor or transfusion), and platelet count \\>= 100 x 10\\^9/L.\n9. Adequate liver function as evidenced by bilirubin \\<= 1.5 times the upper limits of normal (ULN) and alkaline phosphatase, alanine transaminase (ALT), and aspartate transaminase (AST) \\<= 3 x ULN (in the case of liver metastases \\<= 5 x ULN), or in case of bone metastases, liver specific alkaline phosphatase \\<= 3 x ULN.\n10. Patients willing and able to complete the EORTC (European Organization for Research on the Treatment of Cancer) quality of life questionnaire (QLQ-C30 with breast cancer module QLQ-BR23) and to record their pain level on the Visual Analog Scale (VAS).\n11. Patients willing and able to comply with the study protocol for the duration of the study.\n12. Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.\n\nExclusion Criteria:\n\n1. Patients who have received more than three prior chemotherapy regimens for their disease, including adjuvant therapies, or patients who have received more than two prior chemotherapy regimens for advanced disease (other therapies are allowed e.g., anti-estrogens, trastuzumab and radiotherapy).\n2. Patients who have received capecitabine as a prior therapy for their disease.\n3. Patients who have received chemotherapy, radiation, or biological therapy within two weeks, or hormonal therapy, within one week before study treatment start, or any investigational drug within four weeks before study treatment start.\n4. Radiation therapy encompassing \\> 30% of marrow.\n5. Prior treatment with mitomycin C or nitrosourea.\n6. Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.\n7. Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment with study treatment. Any symptoms attributed to brain metastases must be stable for at least 4 weeks before starting study treatment; radiographic stability should be determined by comparing a contrast-enhanced Computed Tomography Scan (CT) or Magnetic Resonance Imaging (MRI) brain scan performed during screening to a prior scan performed at least 4 weeks earlier.\n8. Patients with meningeal carcinomatosis.\n9. Patients who are receiving anti-coagulant therapy with warfarin or related compounds, other than for line patency, and cannot be changed to heparin-based therapy, are not eligible. If a patient is to continue on mini-dose warfarin, then the prothrombin time (PT)/international normalized ratio (INR) must be closely monitored.\n10. Women who are pregnant or breast-feeding; women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test; women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception (considered to be two methods of contraception, one of which must be a barrier method, e.g. condom, diaphragm or cervical cap). Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.\n11. Severe/uncontrolled intercurrent illness/infection.\n12. Significant cardiovascular impairment (history of congestive heart failure \\> New York Heart Association \\[NYHA\\] Grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia).\n13. Patients with organ allografts requiring immunosuppression.\n14. Patients with known positive human immunodeficiency virus (HIV) status.\n15. Patients who have had a prior malignancy, other than carcinoma in situ of the cervix, or non-melanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated \\>= 5 years previously with no subsequent evidence of recurrence.\n16. Patients with pre-existing neuropathy \\> Grade 2.\n17. Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative.\n18. Patients who participated in a prior E7389 clinical trial.\n19. Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study."}, 'identificationModule': {'nctId': 'NCT00337103', 'briefTitle': 'E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes', 'organization': {'class': 'INDUSTRY', 'fullName': 'Eisai Inc.'}, 'officialTitle': 'A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes', 'orgStudyIdInfo': {'id': 'E7389-G000-301'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': '1', 'interventionNames': ['Drug: Eribulin Mesylate']}, {'type': 'ACTIVE_COMPARATOR', 'label': '2', 'interventionNames': ['Drug: Capecitabine']}], 'interventions': [{'name': 'Eribulin Mesylate', 'type': 'DRUG', 'description': '1.4 mg/m\\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days', 'armGroupLabels': ['1']}, {'name': 'Capecitabine', 'type': 'DRUG', 'description': 'Capecitabine 2.5 g/m\\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days', 'armGroupLabels': ['2']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Anaheim', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 33.83529, 'lon': -117.9145}}, {'city': 'La Verne', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 34.10084, 'lon': -117.76784}}, {'city': 'Poway', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 32.96282, 'lon': -117.03586}}, {'city': 'Centralia', 'state': 'Illinois', 'country': 'United States', 'geoPoint': {'lat': 38.52505, 'lon': -89.1334}}, {'city': 'Augusta', 'state': 'Maine', 'country': 'United States', 'geoPoint': {'lat': 44.31062, 'lon': -69.77949}}, {'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'city': 'Jefferson City', 'state': 'Missouri', 'country': 'United States', 'geoPoint': {'lat': 38.5767, 'lon': -92.17352}}, {'city': 'Lebanon', 'state': 'New Hampshire', 'country': 'United States', 'geoPoint': {'lat': 43.64229, 'lon': -72.25176}}, {'city': 'Ephrata', 'state': 'Pennsylvania', 'country': 'United States', 'geoPoint': {'lat': 40.17982, 'lon': -76.17884}}, {'city': 'Cookeville', 'state': 'Tennessee', 'country': 'United States', 'geoPoint': {'lat': 36.16284, 'lon': -85.50164}}, {'city': 'Germantown', 'state': 'Tennessee', 'country': 'United States', 'geoPoint': {'lat': 35.08676, 'lon': -89.81009}}, {'city': 'Amarillo', 'state': 'Texas', 'country': 'United States', 'geoPoint': {'lat': 35.222, 'lon': -101.8313}}, {'city': 'Wenatchee', 'state': 'Washington', 'country': 'United States', 'geoPoint': {'lat': 47.42346, 'lon': -120.31035}}, {'zip': 'C1406FWY', 'city': 'Ciudad Autonoma', 'state': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Hospital General de Agudos Teodoro Alvarez'}, {'city': 'Cuidad Autonoma de Buenos Aires', 'state': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Instituto Argentino de Diagnostico y Tratamiento'}, {'zip': '1898', 'city': 'La Plata', 'state': 'Buenos Aires', 'country': 'Argentina', 'geoPoint': {'lat': -34.92126, 'lon': -57.95442}}, {'city': 'La Plata', 'state': 'Buenos Aires', 'country': 'Argentina', 'geoPoint': {'lat': -34.92126, 'lon': -57.95442}}, {'zip': 'B1629AHJ', 'city': 'Pilar', 'state': 'Buenos Aires', 'country': 'Argentina', 'geoPoint': {'lat': -34.45867, 'lon': -58.91398}}, {'city': 'San Martín', 'state': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Corporacion Medica General San Martin', 'geoPoint': {'lat': -35.02575, 'lon': -57.75317}}, {'zip': 'S2000DSK', 'city': 'Rosario', 'state': 'Santa Fe Province', 'country': 'Argentina', 'geoPoint': {'lat': -32.94682, 'lon': -60.63932}}, {'zip': 'T4000IAK', 'city': 'San Miguel de Tucumán', 'state': 'Tucumán Province', 'country': 'Argentina', 'geoPoint': {'lat': -26.81601, 'lon': -65.21051}}, {'zip': 'Bema 8000', 'city': 'Bahía Blanca', 'country': 'Argentina', 'geoPoint': {'lat': -38.7176, 'lon': -62.26545}}, {'zip': 'C1280AEB', 'city': 'Buenos Aires', 'country': 'Argentina', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Hospital Italiano de Buenos Aires', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'city': 'Buenos Aires', 'country': 'Argentina', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'city': 'Ciudad Autonoma', 'country': 'Argentina'}, {'city': 'Mendoza', 'country': 'Argentina', 'geoPoint': {'lat': -32.88946, 'lon': -68.84582}}, {'zip': 'S3000FFU', 'city': 'Santa Fe', 'country': 'Argentina', 'geoPoint': {'lat': -31.64881, 'lon': -60.70868}}, {'city': 'Bankstown', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Bankstown Hospital, Oncology Trials Unit', 'geoPoint': {'lat': -33.91667, 'lon': 151.03333}}, {'zip': '2077', 'city': 'Hornsby', 'state': 'New South Wales', 'country': 'Australia', 'geoPoint': {'lat': -33.70244, 'lon': 151.09931}}, {'city': 'Liverpool', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Liverpool Hospital, Cancer Therapy Centre', 'geoPoint': {'lat': -33.91938, 'lon': 150.92588}}, {'zip': '5035', 'city': 'Adelaide', 'state': 'South Australia', 'country': 'Australia', 'facility': 'Ashford Cancer Centre', 'geoPoint': {'lat': -34.92866, 'lon': 138.59863}}, {'zip': '7000', 'city': 'Hobart', 'state': 'Tasmania', 'country': 'Australia', 'facility': 'Royal Hobart Hospital', 'geoPoint': {'lat': -42.87936, 'lon': 147.32941}}, {'zip': '3065', 'city': 'Fitzroy', 'state': 'Victoria', 'country': 'Australia', 'facility': "Saint Vincent's Hospital", 'geoPoint': {'lat': -37.79839, 'lon': 144.97833}}, {'zip': '6000', 'city': 'Perth', 'state': 'Western Australia', 'country': 'Australia', 'facility': 'Royal Perth Hospital', 'geoPoint': {'lat': -31.95224, 'lon': 115.8614}}, {'city': 'East Melbourne', 'country': 'Australia', 'facility': 'Epworth Freemasons Hospital', 'geoPoint': {'lat': -37.81667, 'lon': 144.9879}}, {'city': 'Nedlands', 'country': 'Australia', 'facility': 'Sir Charles Gairdner Hospital, Dept. of Medical Oncology', 'geoPoint': {'lat': -31.98184, 'lon': 115.8073}}, {'city': 'South Brisbane', 'country': 'Australia', 'facility': 'Mater Adult Hospital', 'geoPoint': {'lat': -27.48034, 'lon': 153.02049}}, {'zip': '9300', 'city': 'Aalst', 'country': 'Belgium', 'facility': 'OLVZ Aalst, Oncology Service', 'geoPoint': {'lat': 50.93604, 'lon': 4.0355}}, {'zip': '1000', 'city': 'Brussels', 'country': 'Belgium', 'facility': 'Institut Jules Bordet, Medical Oncology Unit', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'zip': '9000', 'city': 'Ghent', 'country': 'Belgium', 'facility': 'Algemeen Ziekenhuis Sint Lucas', 'geoPoint': {'lat': 51.05, 'lon': 3.71667}}, {'city': 'Liège', 'country': 'Belgium', 'facility': 'Centre Hosptialier Universitaire Sart Tilman Liege', 'geoPoint': {'lat': 50.63373, 'lon': 5.56749}}, {'city': 'Florianópolis', 'country': 'Brazil', 'geoPoint': {'lat': -27.59667, 'lon': -48.54917}}, {'city': 'Ijuí', 'country': 'Brazil', 'facility': 'Associacao Hospital de Caridade Ijui', 'geoPoint': {'lat': -28.38778, 'lon': -53.91472}}, {'city': 'Jundiaí', 'country': 'Brazil', 'facility': 'Instituto de Oncologia Ltda', 'geoPoint': {'lat': -23.18639, 'lon': -46.88417}}, {'city': 'Londrina', 'country': 'Brazil', 'facility': 'Proonco Centro de Tratamento Oncologico', 'geoPoint': {'lat': -23.31028, 'lon': -51.16278}}, {'city': 'Porto Alegre', 'country': 'Brazil', 'facility': 'Hospital de Clinicas de Porto Alegre, Servicio de Oncologia', 'geoPoint': {'lat': -30.03283, 'lon': -51.23019}}, {'city': 'Porto Alegre', 'country': 'Brazil', 'facility': 'Hospital Nossa Senhora da Conceicao', 'geoPoint': {'lat': -30.03283, 'lon': -51.23019}}, {'city': 'Recife', 'country': 'Brazil', 'facility': 'Servico de Quimioterapia de Pernambuco-SEQUIPE', 'geoPoint': {'lat': -8.05389, 'lon': -34.88111}}, {'city': 'Ribeirão Preto', 'country': 'Brazil', 'facility': 'Instituto Ribeiraopretano de Combate ao Cancer', 'geoPoint': {'lat': -21.1775, 'lon': -47.81028}}, {'city': 'Salvador', 'country': 'Brazil', 'facility': 'Nucleo de Oncologia da Bahia', 'geoPoint': {'lat': -12.97563, 'lon': -38.49096}}, {'city': 'Santo André', 'country': 'Brazil', 'facility': 'Faculdade de Medicina do ABC', 'geoPoint': {'lat': -23.66389, 'lon': -46.53833}}, {'city': 'São Paulo', 'country': 'Brazil', 'facility': 'Grupo Paulista de Oncologia Integrada Ltda', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'city': 'São Paulo', 'country': 'Brazil', 'facility': 'Hospital das Clinicas de Faculdade de Medicina da Universidade de Sao', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'city': 'São Paulo', 'country': 'Brazil', 'facility': 'Hospital do Cancer de Sao Paulo-AC Camargo', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'city': 'São Paulo', 'country': 'Brazil', 'facility': 'Hospital do Cancer de Sao Paulo-AC. Camargo', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'city': 'São Paulo', 'country': 'Brazil', 'facility': 'Instituto Brasileiro de Controle do Cancer-IBCC', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'city': 'Burgas', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.50651, 'lon': 27.46886}}, {'city': 'Gabrovo', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.87419, 'lon': 25.31823}}, {'city': 'Pleven', 'country': 'Bulgaria', 'geoPoint': {'lat': 43.41791, 'lon': 24.61666}}, {'city': 'Plovdiv', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'city': 'Rousse', 'country': 'Bulgaria', 'geoPoint': {'lat': 43.84872, 'lon': 25.9534}}, {'city': 'Shumen', 'country': 'Bulgaria', 'geoPoint': {'lat': 43.27064, 'lon': 26.92286}}, {'city': 'Sofia', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'city': 'Stara Zagora', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.43205, 'lon': 25.64262}}, {'city': 'Varna', 'country': 'Bulgaria', 'geoPoint': {'lat': 43.21912, 'lon': 27.91024}}, {'city': 'Kingston', 'state': 'Ontario', 'country': 'Canada', 'geoPoint': {'lat': 44.22976, 'lon': -76.48098}}, {'zip': 'H3G 1A4', 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Montreal General Hospital', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': 'H4J 1C5', 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Hopital du Sacre-Coeur de Montreal', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'city': 'Montreal', 'country': 'Canada', 'facility': 'Centre Hospitalier Universitaire de Montreal, Hopital Notre Dame', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'city': 'Thunder Bay', 'country': 'Canada', 'facility': 'Thunder Bay Regional Health Science Centre Northwestern Ontario', 'geoPoint': {'lat': 48.38202, 'lon': -89.25018}}, {'city': 'České Budějovice', 'country': 'Czechia', 'facility': 'Nemocnice Ceske Budejovice, a.s.', 'geoPoint': {'lat': 48.97447, 'lon': 14.47434}}, {'city': 'Olomouc', 'country': 'Czechia', 'facility': 'Onkologicka Klinika, Fakutni Nemocnice', 'geoPoint': {'lat': 49.59552, 'lon': 17.25175}}, {'city': 'Prague', 'country': 'Czechia', 'facility': '1. LF UK, Ustav radiacnej onkologie', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'city': 'Zlin Poiters', 'country': 'Czechia', 'facility': 'Krajska nemocnice T. Bati'}, {'city': 'La Roche-sur-Yon', 'country': 'France', 'facility': 'Centre Hospitalier La Roche sur Yon, CHD les Oudairies', 'geoPoint': {'lat': 46.66974, 'lon': -1.42757}}, {'city': 'Poitiers', 'country': 'France', 'facility': "CHU de Poitiers, Service d'Oncologie Medicale", 'geoPoint': {'lat': 46.58261, 'lon': 0.34348}}, {'city': 'Saint-Priest-en-Jarez', 'country': 'France', 'facility': 'Hopital Nord Saint-Etienne', 'geoPoint': {'lat': 45.4739, 'lon': 4.37678}}, {'city': 'Bochum', 'country': 'Germany', 'facility': 'Augusta-Kranken-Anstalt, Klinik fur Hamatologie und Onkologie', 'geoPoint': {'lat': 51.48165, 'lon': 7.21648}}, {'city': 'Hamburg', 'country': 'Germany', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'city': 'Homburg', 'country': 'Germany', 'geoPoint': {'lat': 49.32637, 'lon': 7.33867}}, {'city': 'Magdeburg', 'country': 'Germany', 'facility': 'Universitatsfrauenklinik Magdeburg', 'geoPoint': {'lat': 52.13129, 'lon': 11.63189}}, {'city': 'Rostock', 'country': 'Germany', 'geoPoint': {'lat': 54.0887, 'lon': 12.14049}}, {'city': 'Pátrai', 'country': 'Greece', 'geoPoint': {'lat': 38.2462, 'lon': 21.73508}}, {'city': 'Gyor', 'state': 'Budapest', 'country': 'Hungary'}, {'city': 'Debrecen', 'country': 'Hungary', 'facility': 'Debrecen University', 'geoPoint': {'lat': 47.53167, 'lon': 21.62444}}, {'city': 'Debrecen', 'country': 'Hungary', 'geoPoint': {'lat': 47.53167, 'lon': 21.62444}}, {'zip': '5700', 'city': 'Gyula', 'country': 'Hungary', 'geoPoint': {'lat': 46.65, 'lon': 21.28333}}, {'city': 'Pécs', 'country': 'Hungary', 'facility': 'Pecsi Tudomanyegyetem, Onkoterapias Intezet', 'geoPoint': {'lat': 46.07617, 'lon': 18.22814}}, {'city': 'Szeged', 'country': 'Hungary', 'geoPoint': {'lat': 46.253, 'lon': 20.14824}}, {'city': 'Veszprém', 'country': 'Hungary', 'geoPoint': {'lat': 47.09327, 'lon': 17.91149}}, {'city': 'Ashkelon', 'country': 'Israel', 'facility': 'Barzilai Medical Center', 'geoPoint': {'lat': 31.66926, 'lon': 34.57149}}, {'city': 'Beersheba', 'country': 'Israel', 'facility': 'Soroka Medical Center', 'geoPoint': {'lat': 31.25181, 'lon': 34.7913}}, {'city': 'Jerusalem', 'country': 'Israel', 'facility': 'Sharet Institute of Oncology', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'city': 'Kfar Saba', 'country': 'Israel', 'facility': 'Meir Hospital, Sapir Medical Center', 'geoPoint': {'lat': 32.175, 'lon': 34.90694}}, {'city': 'Petah Tikva', 'country': 'Israel', 'facility': 'Rabin Medical Center', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'city': 'Rehovot', 'country': 'Israel', 'facility': 'Kaplan Medical Center', 'geoPoint': {'lat': 31.89421, 'lon': 34.81199}}, {'city': 'Tel Litwinsky', 'country': 'Israel', 'facility': 'The Chaim Sheba Medical Center', 'geoPoint': {'lat': 32.05096, 'lon': 34.84588}}, {'city': 'Ancona', 'country': 'Italy', 'geoPoint': {'lat': 43.60717, 'lon': 13.5103}}, {'city': 'Lugo', 'country': 'Italy', 'facility': 'Unita Operativa de Oncologia', 'geoPoint': {'lat': 44.42137, 'lon': 11.91094}}, {'city': 'Meldola', 'country': 'Italy', 'geoPoint': {'lat': 44.12775, 'lon': 12.0626}}, {'city': 'Modena', 'country': 'Italy', 'geoPoint': {'lat': 44.64783, 'lon': 10.92539}}, {'city': 'Pesaro', 'country': 'Italy', 'facility': 'Azienda Ospedaliera San Salvatore', 'geoPoint': {'lat': 43.90921, 'lon': 12.9164}}, {'city': 'Ravenna', 'country': 'Italy', 'facility': 'Ospedale Civile S. Maria delle Croci', 'geoPoint': {'lat': 44.41344, 'lon': 12.20121}}, {'city': 'Rimini', 'country': 'Italy', 'facility': 'UO di Onco-ematologia', 'geoPoint': {'lat': 44.05755, 'lon': 12.56528}}, {'city': 'Sassari', 'country': 'Italy', 'geoPoint': {'lat': 40.72586, 'lon': 8.55552}}, {'city': 'Chihuahua City', 'country': 'Mexico', 'facility': 'Centro Estatal de Cancerologia', 'geoPoint': {'lat': 28.63528, 'lon': -106.08889}}, {'city': 'Monterrey', 'country': 'Mexico', 'geoPoint': {'lat': 25.68435, 'lon': -100.31721}}, {'city': 'Morelia', 'country': 'Mexico', 'facility': 'Consultorio del Dr. Trigueros', 'geoPoint': {'lat': 19.70078, 'lon': -101.18443}}, {'city': 'Bialystok', 'country': 'Poland', 'facility': 'Regionalny Osrodek Onkologii', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'city': 'Bytom', 'country': 'Poland', 'geoPoint': {'lat': 50.34802, 'lon': 18.93282}}, {'city': 'Elblag', 'country': 'Poland', 'geoPoint': {'lat': 54.1522, 'lon': 19.40884}}, {'zip': '80-210', 'city': 'Gdansk', 'country': 'Poland', 'facility': 'Wojewodzkie Centrum Onkologii', 'geoPoint': {'lat': 54.35227, 'lon': 18.64912}}, {'city': 'Krakow', 'country': 'Poland', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '10-513', 'city': 'Olsztyn', 'country': 'Poland', 'geoPoint': {'lat': 53.78376, 'lon': 20.49272}}, {'zip': '44-200', 'city': 'Rybnik', 'country': 'Poland', 'geoPoint': {'lat': 50.09713, 'lon': 18.54179}}, {'city': 'Torun', 'country': 'Poland', 'geoPoint': {'lat': 53.01375, 'lon': 18.59814}}, {'zip': '51-124', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'Wojewodzki Szpital Specjalistyczny', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '400015', 'city': 'Cluj-Napoca', 'state': 'Cluj', 'country': 'Romania', 'geoPoint': {'lat': 46.76667, 'lon': 23.6}}, {'zip': '10825', 'city': 'Bucharest', 'country': 'Romania', 'facility': 'Spitalul Militar Central Bucuresti', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'city': 'Bucharest', 'country': 'Romania', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'city': 'Cluj-Napoca', 'country': 'Romania', 'geoPoint': {'lat': 46.76667, 'lon': 23.6}}, {'zip': '700106', 'city': 'Iași', 'country': 'Romania', 'facility': 'Centrul de Oncologie Medicala', 'geoPoint': {'lat': 47.16667, 'lon': 27.6}}, {'city': 'Sibiu', 'country': 'Romania', 'facility': 'Spitalul Clinic Judetean Sibiu', 'geoPoint': {'lat': 45.8, 'lon': 24.15}}, {'city': 'Timișoara', 'country': 'Romania', 'geoPoint': {'lat': 45.75372, 'lon': 21.22571}}, {'zip': '150054', 'city': 'Yaroslavl', 'state': 'Yaroslavlr', 'country': 'Russia', 'facility': 'Regional Oncology Dispensary', 'geoPoint': {'lat': 57.62987, 'lon': 39.87368}}, {'city': 'Barnaul', 'country': 'Russia', 'geoPoint': {'lat': 53.36199, 'lon': 83.72786}}, {'city': "Kazan'", 'country': 'Russia', 'geoPoint': {'lat': 55.78874, 'lon': 49.12214}}, {'city': 'Kirov', 'country': 'Russia', 'geoPoint': {'lat': 58.59809, 'lon': 49.65783}}, {'city': 'Krasnodar', 'country': 'Russia', 'geoPoint': {'lat': 45.04534, 'lon': 38.98178}}, {'zip': '115478', 'city': 'Moscow', 'country': 'Russia', 'facility': 'Blokhin Cancer Research Centre', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'city': 'Moscow', 'country': 'Russia', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'city': 'Nizhny Novgorod', 'country': 'Russia', 'geoPoint': {'lat': 56.32867, 'lon': 44.00205}}, {'city': 'Obninsk', 'country': 'Russia', 'geoPoint': {'lat': 55.10993, 'lon': 36.61238}}, {'city': 'Rostov-on-Don', 'country': 'Russia', 'geoPoint': {'lat': 47.21997, 'lon': 39.70769}}, {'city': 'Saint Petersburg', 'country': 'Russia', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'city': 'Saratov', 'country': 'Russia', 'geoPoint': {'lat': 51.54048, 'lon': 45.9901}}, {'city': 'Sochi', 'country': 'Russia', 'geoPoint': {'lat': 43.59699, 'lon': 39.72477}}, {'city': 'Tomsk', 'country': 'Russia', 'geoPoint': {'lat': 56.50049, 'lon': 84.98216}}, {'city': 'Vladimir', 'country': 'Russia', 'geoPoint': {'lat': 56.13854, 'lon': 40.39976}}, {'city': 'Singapore', 'country': 'Singapore', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'zip': '4091', 'city': 'Mayville', 'state': 'Durban', 'country': 'South Africa', 'geoPoint': {'lat': -29.85, 'lon': 30.98333}}, {'city': 'Pretoria', 'state': 'Gaunteng', 'country': 'South Africa', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}, {'city': 'Groenkloof', 'state': 'Pretoria', 'country': 'South Africa', 'geoPoint': {'lat': -31.78089, 'lon': 25.50906}}, {'city': 'Cape Town', 'country': 'South Africa', 'facility': 'Panorama Medical Centre', 'geoPoint': {'lat': -33.92584, 'lon': 18.42322}}, {'zip': '4091', 'city': 'Durban', 'country': 'South Africa', 'geoPoint': {'lat': -29.8579, 'lon': 31.0292}}, {'city': 'Johannesburg', 'country': 'South Africa', 'geoPoint': {'lat': -26.20227, 'lon': 28.04363}}, {'zip': '2199', 'city': 'Sandton', 'country': 'South Africa', 'geoPoint': {'lat': -26.104, 'lon': 28.054}}, {'city': 'Barakaldo', 'state': 'Vizcaya', 'country': 'Spain', 'geoPoint': {'lat': 43.29639, 'lon': -2.98813}}, {'city': 'A Coruña', 'country': 'Spain', 'geoPoint': {'lat': 43.37135, 'lon': -8.396}}, {'city': 'Barcelona', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'city': 'Guadalajara', 'country': 'Spain', 'geoPoint': {'lat': 40.62862, 'lon': -3.16185}}, {'city': 'Seville', 'country': 'Spain', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'city': 'Valencia', 'country': 'Spain', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'city': 'Changhua', 'country': 'Taiwan', 'geoPoint': {'lat': 24.0692, 'lon': 120.5512}}, {'city': 'Taichung', 'country': 'Taiwan', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'city': 'Tainan', 'country': 'Taiwan', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}, {'city': 'Taipei', 'country': 'Taiwan', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'city': 'Yung-Kang City', 'country': 'Taiwan'}, {'city': 'Chernihiv', 'country': 'Ukraine', 'geoPoint': {'lat': 51.50541, 'lon': 31.28656}}, {'city': 'Dnipro', 'country': 'Ukraine', 'geoPoint': {'lat': 48.46664, 'lon': 35.04066}}, {'city': 'Donetsk', 'country': 'Ukraine', 'geoPoint': {'lat': 48.023, 'lon': 37.80224}}, {'city': 'Kharkiv', 'country': 'Ukraine', 'geoPoint': {'lat': 49.98177, 'lon': 36.25475}}, {'city': 'Khmelnytskyi', 'country': 'Ukraine', 'geoPoint': {'lat': 49.41835, 'lon': 26.97936}}, {'city': 'Kiev', 'country': 'Ukraine', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'city': 'Kryvyi Rih', 'country': 'Ukraine', 'geoPoint': {'lat': 47.90572, 'lon': 33.39404}}, {'city': 'Kyiv', 'country': 'Ukraine', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'city': 'Lviv', 'country': 'Ukraine', 'geoPoint': {'lat': 49.83826, 'lon': 24.02324}}, {'city': 'Odesa', 'country': 'Ukraine', 'geoPoint': {'lat': 46.48572, 'lon': 30.74383}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Eisai Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}